|
|
|
|
| LEADER |
00000cam a2200000 a 4500 |
| 001 |
SCIDIR_on1144869878 |
| 003 |
OCoLC |
| 005 |
20231120010441.0 |
| 006 |
m o d |
| 007 |
cr |n||||||||| |
| 008 |
200317s2020 ne o 000 0 eng d |
| 040 |
|
|
|a YDX
|b eng
|e pn
|c YDX
|d OPELS
|d UKAHL
|d N$T
|d UKMGB
|d OCLCF
|d EBLCP
|d UHL
|d OCLCO
|d OCLCA
|d OCLCQ
|d OCLCO
|d SFB
|d OCLCQ
|d OCLCO
|
| 015 |
|
|
|a GBC031080
|2 bnb
|
| 016 |
7 |
|
|a 019726192
|2 Uk
|
| 020 |
|
|
|a 9780128200179
|q (electronic bk.)
|
| 020 |
|
|
|a 0128200170
|q (electronic bk.)
|
| 020 |
|
|
|z 9780128200162
|
| 020 |
|
|
|z 0128200162
|
| 035 |
|
|
|a (OCoLC)1144869878
|
| 050 |
|
4 |
|a RC280.B8
|
| 082 |
0 |
4 |
|a 616.99/449
|2 23
|
| 245 |
0 |
0 |
|a Nanomedicines for breast cancer theranostics /
|c edited by Nanasaheb D. Thorat, Joanna Bauer.
|
| 260 |
|
|
|a Amsterdam :
|b Elsevier,
|c 2020.
|
| 300 |
|
|
|a 1 online resource
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 336 |
|
|
|a still image
|b sti
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
0 |
|
|a Micro and nano technologies series
|
| 505 |
0 |
|
|a Front Cover -- Nanomedicines for Breast Cancer Theranostics -- Nanomedicines for Breast Cancer Theranostics -- Copyright -- Contents -- Contributors -- Biography -- Preface -- Acknowledgment -- 1 -- Nanomedicine -- 1 -- Nanomedicine: next generation modality of breast cancer therapeutics -- 1.1 Introduction -- 1.1.1 Breast cancer -- 1.1.2 Breast cancer grading -- 1.1.3 Conventional breast cancer therapies -- 1.2 Cancer nanomedicine -- Acknowledgments -- References -- 2 -- Physical and chemical properties of nanomaterials -- 2.1 Introduction -- 2.2 Physical properties -- 2.2.1 Melting point
|
| 505 |
8 |
|
|a 2.2.2 Mechanical properties -- 2.2.2.1 Hardness, plasticity, and Young's modulus/strength -- 2.2.3 Optical properties -- 2.2.4 Magnetic properties -- 2.2.4.1 Superparamagnetic behavior -- 2.2.4.2 Giant magnetoresistance (GMR) -- 2.2.4.3 Tunneling magnetoresistance (TMR) -- 2.3 Chemical properties -- 2.3.1 Surface energy -- 2.3.2 Chemical potential -- 2.3.3 Oxidation process at nanoscale -- 2.3.4 Catalysis -- 2.3.5 Functionalization of nanostructures -- 2.3.5.1 Surface functionalization -- 2.3.5.2 End wall functionalization -- 2.3.5.3 Inner wall functionalization -- References
|
| 505 |
8 |
|
|a 3 -- Biological prospectives of hybrid nanostructures -- 3.1 Introduction -- 3.2 Hybrid nanostructures -- 3.3 Breast cancer -- 3.4 Current trends and challenges in treatments of breast cancer -- 3.5 Hybrid nanostructures in breast cancer nanotheranostics -- 3.5.1 Liposomal hybrid nanoparticles -- 3.5.2 Micelles hybrid nanostructures -- 3.5.3 Porous silica-based hybrid nanoparticles -- 3.5.4 Polymeric hybrid nanoparticles -- 3.5.5 Gold-based hybrid nanoparticles -- 3.5.6 Nanotube-based hybrid nanoparticles -- 3.6 Conclusion and future perspectives -- References
|
| 505 |
8 |
|
|a 4 -- Novel hybrid nanostructure for breast cancer application -- 4.1 Introduction -- 4.2 Hybrid nanostructures in breast cancer applications -- 4.2.1 Liposomal hybrid nanostructures -- 4.2.2 Silica based hybrid nanostructures -- 4.2.3 Hybrid magnetic nanostructures -- 4.2.4 Gold based hybrid nanostructures -- 4.2.5 Carbon-based hybrid nanostructures -- 4.3 Conclusion -- References -- 2 -- Theranostics -- 5 -- Synergy between nanoparticles and breast cancer theranostics -- 5.1 Introduction -- 5.2 Nanoparticles for synergistic breast cancer diagnostics -- 5.2.1 Monomodal diagnostics
|
| 505 |
8 |
|
|a 5.2.1.1 Fluorescence imaging (FI) -- 5.2.1.1.1 MCh-QDs -- 5.2.1.1.2 CQDs -- 5.2.1.1.3 SPDs -- 5.2.1.2 Computed tomography (CT) -- 5.2.1.3 Magnetic resonance imaging (MRI) -- 5.2.2 Bimodal diagnostics -- 5.2.2.1 FI and CT -- 5.2.2.2 FI and MRI -- 5.2.2.3 CT and MRI -- 5.2.3 Trimodal diagnostics -- 5.3 Nanoparticles for synergistic breast cancer therapeutics -- 5.3.1 Monomodal therapeutics -- 5.3.1.1 Chemotherapy (CHT) -- 5.3.1.2 Magnetic hyperthermia therapy (MHT) -- 5.3.1.3 Photodynamic/photothermal therapy (PDT/PTT) -- 5.3.2 Bimodal therapeutics -- 5.3.2.1 CHT and MHT -- 5.3.2.2 CHT and PDT/PTT
|
| 650 |
|
0 |
|a Breast
|x Cancer
|x Chemotherapy.
|
| 650 |
|
0 |
|a Nanomedicine.
|
| 650 |
1 |
2 |
|a Breast Neoplasms
|0 (DNLM)D001943
|
| 650 |
2 |
2 |
|a Neoplasms
|x drug therapy
|0 (DNLM)D009369Q000188
|
| 650 |
|
2 |
|a Nanomedicine
|0 (DNLM)D050997
|
| 650 |
|
6 |
|a Sein
|0 (CaQQLa)201-0071080
|x Cancer
|0 (CaQQLa)201-0071080
|x Chimioth�erapie.
|0 (CaQQLa)201-0379519
|
| 650 |
|
6 |
|a Nanom�edecine.
|0 (CaQQLa)201-0448752
|
| 650 |
|
7 |
|a Breast
|x Cancer
|x Chemotherapy
|2 fast
|0 (OCoLC)fst00838266
|
| 650 |
|
7 |
|a Nanomedicine
|2 fast
|0 (OCoLC)fst01744350
|
| 700 |
1 |
|
|a Thorat, Nanasaheb D.
|
| 700 |
1 |
|
|a Bauer, Joanna.
|
| 776 |
0 |
8 |
|i Print version:
|z 0128200162
|z 9780128200162
|w (OCoLC)1127121922
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780128200162
|z Texto completo
|
